Triple Negative Breast Cancer Clinical Trials 2022

Browse 247 Triple Negative Breast Cancer Medical Studies Across 510 Cities
19 Phase 3 Trial · 2712 Triple Negative Breast Cancer Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Triple Negative Breast Cancer Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of Carolina BioOncology Institute in Huntersville, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Triple Negative Breast Cancer (for Tumors > 5 Cm)for Triple Negative Breast Neoplasms

This trial will study whether the amount a tumor shrinks before surgery can predict how much of the tumor will remain after surgery.

Phase 2

Waitlist Available

FDA Approved Drug

Baylor College of Medicine (+1 Sites)Mothaffar Rimawi, MD

Image of City of Hope Comprehensive Cancer Center ( Site 1001) in Duarte, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Pembrolizumab/Vibostolimab Co-Formulationfor Oral Squamous Cell Carcinoma

This trial is testing a new cancer drug, given alone or with other anticancer therapies, to see if it is safe and effective in treating people with advanced solid tumors.

Phase 2

Recruiting

FDA Approved Drug

City of Hope Comprehensive Cancer Center ( Site 1001) (+11 Sites)Medical DirectorMerck Sharp & Dohme Corp.

Image of New Experimental Therapeutics of San Antonio (NEXT Oncology) in San Antonio, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

ELU001for Ovary Cancer

This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.

Phase 1 & 2

Recruiting

Has No Placebo

New Experimental Therapeutics of San Antonio (NEXT Oncology) (+8 Sites)Eliel Bayever, MBBCh, MRCPElucida Oncology

Image of Cedars Sinai Medical Center in West Hollywood, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

TAK-676for Carcinoma, Non-Small-Cell Lung

This trial is testing a combination of two immunotherapy drugs, TAK-676 and pembrolizumab, to see if they can improve outcomes for people with non-small cell lung cancer, triple-negative breast cancer, and squamous cell carcinoma of the head and neck.

Phase 1

Recruiting

FDA Approved Drug

Cedars Sinai Medical Center (+6 Sites)Study DirectorTakeda

Image of Sarah Cannon Research Institute at HealthONE in Denver, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

BT8009for Cancer of Esophagus

This trial is testing a new drug called BT8009, either alone or combined with another drug called nivolumab, in people with advanced solid tumors. The goal is to see if it is safe and effective.

Phase 1 & 2

Recruiting

FDA Approved Drug

Sarah Cannon Research Institute at HealthONE (+9 Sites)Meredith McKean, MD, MPHBicycleTx Limited

Image of Research Site in Baltimore, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

AZD8701for Melanoma

This trial is testing a new drug, AZD8701, to see if it is safe and effective in treating certain types of solid tumors. The drug will be tested alone and in combination with another drug, durvalumab.

Phase 1

Recruiting

FDA Approved Drug

Research Site (+10 Sites)AstraZeneca

Image of Comprehensive Blood and Cancer Center Dept. of CBCC (2) in Bakersfield, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Alpelisibfor Triple Negative Breast Neoplasms

This trial is testing a new cancer drug to see if it's safe and effective for treating advanced triple negative breast cancer in patients with either a PIK3CA mutation or PTEN loss.

Comprehensive Blood and Cancer Center Dept. of CBCC (2) (+25 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals

Image of UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138) in San Francisco, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Pembrolizumabfor Triple Negative Breast Neoplasms

This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.

Phase 2

Waitlist Available

FDA Approved Drug

UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138) (+26 Sites)Medical DirectorMerck Sharp & Dohme Corp.

Image of Research Site in Tucson, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Capivasertibfor Triple Negative Breast Neoplasms

This trial is testing a new combination of drugs to treat TNBC compared to the current standard of care.

Phase 3

Recruiting

FDA Approved Drug

Research Site (+1 Sites)Peter Schmid, MD,PhD,FRCPAstraZeneca

Image of Research Site in Boston, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Durvalumabfor Triple Negative Breast Neoplasms

This trial will test the effectiveness of durvalumab, a new immunotherapy drug, in combination with other cancer treatments, for people with first-line metastatic triple negative breast cancer.

Phase 1 & 2

Waitlist Available

FDA Approved Drug

Research Site (+9 Sites)Peter Schmid, MD, PhDAstraZeneca

Image of University of Alabama at Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Pembrolizumabfor Triple Negative Breast Neoplasms

This trial is testing a new cancer treatment involving two drugs. It will study the side effects and if the drugs are effective in treating triple-negative breast cancer.

Phase 1 & 2

Recruiting

FDA Approved Drug

University of Alabama at Birmingham (+23 Sites)Zejing Wang, MD, PhDMerck Sharp & Dohme LLC

Image of Washington University School of Medicine in Saint Louis, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Neoantigen DNA Vaccinefor Triple Negative Breast Neoplasms

This trial is testing a neoantigen DNA vaccine in patients with triple negative breast cancer. The vaccine will be given either alone or with the drug durvalumab.

Phase 1

Waitlist Available

FDA Approved Drug

Washington University School of MedicineWilliam Gillanders, M.D.MedImmune LLC

Image of Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089) in Scottsdale, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Pembrolizumabfor Triple Negative Breast Neoplasms

This trial is testing a new cancer treatment of pembrolizumab (MK-3475) combined with chemotherapy vs. chemotherapy alone in participants who have triple negative breast cancer.

Phase 3

Waitlist Available

FDA Approved Drug

Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089) (+53 Sites)Medical DirectorMerck Sharp & Dohme Corp.

Phase-Based Progress Estimates

Effectiveness

Safety

Combination Of Veliparib + Lapatinibfor Breast Cancer

This trial will study the effectiveness of two drugs, Veliparib and Lapatinib, for treating metastatic triple negative breast cancer.

Waitlist Available

FDA Approved Drug

University of Alabama at BirminghamAndres Forero, MDAbbVie

Image of University of Alabama in Birmingham, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Cisplatinfor Breast Cancer

This trial is testing if a certain kind of chemotherapy is more effective than another kind in treating a specific type of breast cancer.

Phase 2

Waitlist Available

FDA Approved Drug

University of Alabama (+19 Sites)Erica Mayer, MDMyriad Genetics, Inc.

Phase-Based Progress Estimates

Effectiveness

Safety

Ladiratuzumab Vedotinfor Triple Negative Breast Neoplasms

This trial will study the safety and effectiveness of a new cancer drug, given alone or with another drug.

Phase 1

Recruiting

FDA Approved Drug

University of Alabama at Birmingham (+29 Sites)Phillip Garfin, MDSeagen Inc.

Image of Rocky Mountain Cancer Centers in Colorado Springs, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Enzalutamidefor Triple Negative Breast Neoplasms

This trial will test if a new medication, enzalutamide, is safe and effective for treating patients with advanced breast cancer who express the androgen receptor, but not the estrogen or progesterone receptor, and are not Her2 amplified.

Phase 2

Waitlist Available

FDA Approved Drug

Rocky Mountain Cancer Centers (+80 Sites)Pfizer CT.gov Call CenterAstellas Pharma Inc

Image of UCLA School of Medicine in Los Angeles, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

LGK974for Melanoma

This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.

Phase 1

Recruiting

Has No Placebo

UCLA School of Medicine (+4 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals

Image of Cedars Sinai Medical Center in Los Angeles, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Cediranib Maleatefor High Grade Ovarian Serous Adenocarcinoma

This trial is testing the side effects and best dose of two drugs, cediranib and olaparib, compared to olaparib alone, in treating patients with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer.

Phase 1 & 2

Waitlist Available

FDA Approved Drug

Cedars Sinai Medical Center (+13 Sites)Joyce F Liu

Phase-Based Progress Estimates

Effectiveness

Safety

Trilaciclib With Or Without Trastuzumab + Pertuzumabfor Breast Cancer

This trial is testing new drugs for breast cancer and trying to find which early indicators predict success for different types of tumors.

Phase 2

Recruiting

FDA Approved Drug

University of Alabama at Birmingham (+27 Sites)Laura Esserman, MD, MBA

Image of Mayo Clinic in Arizona in Scottsdale, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Ruxolitinib Phosphatefor Bone and Bones

This trial is testing the side effects and best dose of a drug when given with another drug to treat stage IV triple negative breast cancer.

Phase 1

Recruiting

FDA Approved Drug

Mayo Clinic in ArizonaDonald W Northfelt

Phase-Based Progress Estimates

Effectiveness

Safety

Multi-epitope Folate Receptor Alpha Peptide Vaccinefor Breast

This trial is testing a vaccine made from a person's white blood cells mixed with tumor proteins, given with sargramostim (GM-CSF) and cyclophosphamide, to see if it can prevent the recurrence of stage 1-3 triple negative breast cancer.

Phase 2

Waitlist Available

FDA Approved Drug

Mayo Clinic in Arizona (+10 Sites)Kathryn J Ruddy

25 Triple Negative Breast Cancer Clinical Trials Near Me

Top Hospitals for Triple Negative Breast Cancer Clinical Trials

Memorial Sloan Kettering Cancer Center

New York

22Active Trials

33All Time Trials for Triple Negative Breast Cancer

2011First Triple Negative Breast Cancer Trial

Dana-Farber Cancer Institute

Boston

22Active Trials

30All Time Trials for Triple Negative Breast Cancer

2007First Triple Negative Breast Cancer Trial

Top Cities for Triple Negative Breast Cancer Clinical Trials

Houston

96Active Trials

M D Anderson Cancer CenterTop Active Site

Boston

95Active Trials

Dana-Farber Cancer InstituteTop Active Site

Triple Negative Breast Cancer Clinical Trials 2022

Browse 247 Triple Negative Breast Cancer Medical Studies Across 510 Cities19 Phase 3 Trial · 2712 Triple Negative Breast Cancer Clinics

NUV-868for Prostate Cancer

SGN-PDL1Vfor Esophageal Squamous Cell Carcinoma

SGN-B7H4Vfor Triple Negative Breast Neoplasms

Triple Negative Breast Cancer (for Tumors > 5 Cm)for Triple Negative Breast Neoplasms

Pembrolizumab/Vibostolimab Co-Formulationfor Oral Squamous Cell Carcinoma

ELU001for Ovary Cancer

TAK-676for Carcinoma, Non-Small-Cell Lung

BT8009for Cancer of Esophagus

AZD8701for Melanoma

Alpelisibfor Triple Negative Breast Neoplasms

Pembrolizumabfor Triple Negative Breast Neoplasms

Capivasertibfor Triple Negative Breast Neoplasms

Durvalumabfor Triple Negative Breast Neoplasms

Pembrolizumabfor Triple Negative Breast Neoplasms

Neoantigen DNA Vaccinefor Triple Negative Breast Neoplasms

Pembrolizumabfor Triple Negative Breast Neoplasms

Combination Of Veliparib + Lapatinibfor Breast Cancer

Cisplatinfor Breast Cancer

Ladiratuzumab Vedotinfor Triple Negative Breast Neoplasms

Enzalutamidefor Triple Negative Breast Neoplasms

LGK974for Melanoma

Cediranib Maleatefor High Grade Ovarian Serous Adenocarcinoma

Trilaciclib With Or Without Trastuzumab + Pertuzumabfor Breast Cancer

Ruxolitinib Phosphatefor Bone and Bones

Multi-epitope Folate Receptor Alpha Peptide Vaccinefor Breast

Browse 247 Triple Negative Breast Cancer Medical Studies Across 510 Cities
19 Phase 3 Trial · 2712 Triple Negative Breast Cancer Clinics